Skip to main content

Patou Gary's Form 4 filing

Xenon Pharmaceuticals Inc.XENE · filed Nov 22, 2024

Accession no.
0000950170-24-130378
Filed
Nov 22, 2024
Trade date
Nov 22, 2024
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $200.9K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Patou GaryCIK 0001283535Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 22, 2024Common SharesMOption exerciseAcquired+3,500$7.38+$25,83027,073Direct
Nov 22, 2024Common SharesFTax withholdingDisposed−649$39.80F1−$25,830.226,424Direct
Nov 22, 2024Common SharesSSaleDisposed−2,851$41.11−$117,204.6123,573Direct
Nov 22, 2024Common SharesMOption exerciseAcquired+3,086$13.48+$41,599.2826,659Direct
Nov 22, 2024Common SharesFTax withholdingDisposed−1,046$39.80F1−$41,630.825,613Direct
Nov 22, 2024Common SharesSSaleDisposed−2,040$41.05−$83,74223,573Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 22, 2024Common SharesMOption exerciseDisposed−3,500$0.00$00Direct
Nov 22, 2024Common SharesMOption exerciseDisposed−3,086$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents the closing price of the Company's common shares on November 21, 2024 for purposes of net settlement calculations.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)